Cell and gene therapy consulting firm submits draft AAV purity guidance to FDA

Back in September, the FDA held a two-day adcomm on gene therapy. At the time, hopes were that talks and discussions could offer a clear direction for the field’s future — and people came away disappointed as no solid recommendations or conclusions were offered. Anthony Davies, the chief behind Dark...

Click to view original post